Evidence map›Paper›PMID 40692395›Full record

ArticleAdvanced healthcare materials2025

Rolling Ultrasharp Microneedle Spheres Enable Topical Delivery of Biologics Through the Skin.

Theocharis Nikiforos Iordanidis, Argyris Spyrou, Samantha Roudi, Fredrik J Swartling, Göran Stemme, Samir El Andaloussi, Niclas Roxhed

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Theocharis Nikiforos IordanidisKTH Royal Institute of Technology, Division of Micro and Nanosystems, Stockholm, 100 44, Sweden.ORCID 0009-0003-4252-9973
Argyris SpyrouKTH Royal Institute of Technology, Division of Micro and Nanosystems, Stockholm, 100 44, Sweden.
Samantha RoudiDivision of Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institutet, ANA Futura, Huddinge, Stockholm, 141 52, Sweden.
Fredrik J SwartlingDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, 751 85, Sweden.
Göran StemmeKTH Royal Institute of Technology, Division of Micro and Nanosystems, Stockholm, 100 44, Sweden.
Samir El AndaloussiDivision of Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institutet, ANA Futura, Huddinge, Stockholm, 141 52, Sweden.
Niclas RoxhedKTH Royal Institute of Technology, Division of Micro and Nanosystems, Stockholm, 100 44, Sweden.ORCID 0000-0002-7147-6730

Funding

Cancerfonden 211762Pj01HErling-Persson Foundation 2022 0104European Research Council (ERC) 101001374Hjärnfonden FO2024-0073-TK-113LEO Foundation LF-OC-24-001513MedTechLabsSjöberg foundation Flagship(CAR-T)Vetenskapsrådet 2019-05452
6 · The paper itself

Abstract

Topical drug delivery offers a localized and patient-friendly method for treating skin diseases and subcutaneous lesions. However, the outermost skin barrier - the stratum corneum (SC) - hinders the delivery of large molecules such as biopharmaceuticals. This study introduces rolling ultraminiaturized microneedle spheres (RUMS) as a novel solution that enables topical delivery of messenger RNA (mRNA) without the need for chemical enhancers or techniques like electroporation, iontophoresis, or microneedle patches. RUMS are engineered spherical microparticles that gently roll over the skin, creating numerous micropores while minimizing tissue damage. In ex vivo porcine skin experiments, 25 RUMS generated approximately 4,500 pores within 10 seconds, achieving penetration depths of around 20 micrometers and increasing skin permeability by up to 100-fold. In vivo studies in mice showed that combining RUMS with topical doxycycline led to a ~50% tumor size reduction within two weeks and full recovery by four weeks. In contrast, doxycycline or RUMS alone offered limited therapeutic benefit. Rapid skin healing was observed due to the small pore size. Additionally, topical delivery of lipid nanoparticle-encapsulated luciferase (luc)-encoding mRNA was successfully demonstrated in mice. Overall, use of RUMS presents a simple, painless, and potentially well-tolerated technique for enabling transdermal topical delivery of biologics.

Indexed as

Biological ProductsDrug Delivery SystemsNeedlesSkinAdministration, CutaneousAnimalsFemaleHumansMiceNanoparticlesRNA, MessengerSwineBiological ProductsRNA, Messengerbiopharmaceuticalsdrug deliverymicroneedlerolling particlestransdermal

Identifiers

PMID40692395
PMCPMC12538527

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.